Loading
Life sciences · Journal article
Chinese Medical Journal · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT: The treatment landscape for advanced prostate cancer (PCa) has significantly evolved in recent years, marked by the introduction of several novel therapies. Targeting the androgen receptor (AR) remains a cornerstone of treatment, with drugs, such as abiraterone and next-generation antiandrogens, providing substantial benefits. Poly (ADP-ribose) polymerase (PARP) inhibitors, both as monotherapies and in combination with other agents, have demonstrated promise, particularly for patients with deoxyribonucleic acid (DNA) repair defects. While immunotherapy has historically shown limited efficacy in the treatment of PCa, recent findings from the CONTACT‑02 study suggest a potential breakthrough, demonstrating improved patient outcomes with the combined use of atezolizumab and cabozantinib. Additionally, emerging therapies targeting cyclin-dependent kinases 4 and 6 (CDK4/6), the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, and epigenetic modifications offer new treatment possibilities. These advancements, coupled with ongoing research into combination therapies and novel drug targets, hold the potential to further enhance outcomes for patients with advanced PCa. This article review summarizes the latest transformative therapies in PCa care.